IL158071A0 - Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer - Google Patents
Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancerInfo
- Publication number
- IL158071A0 IL158071A0 IL15807102A IL15807102A IL158071A0 IL 158071 A0 IL158071 A0 IL 158071A0 IL 15807102 A IL15807102 A IL 15807102A IL 15807102 A IL15807102 A IL 15807102A IL 158071 A0 IL158071 A0 IL 158071A0
- Authority
- IL
- Israel
- Prior art keywords
- health
- related quality
- progression
- patients
- disease
- Prior art date
Links
- 206010060862 Prostate cancer Diseases 0.000 title 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002349 favourable effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/832,752 US20030022811A1 (en) | 2001-04-11 | 2001-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| US11848602A | 2002-04-08 | 2002-04-08 | |
| PCT/US2002/011397 WO2002085351A1 (en) | 2001-04-11 | 2002-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL158071A0 true IL158071A0 (en) | 2004-03-28 |
Family
ID=26816420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15807102A IL158071A0 (en) | 2001-04-11 | 2002-04-11 | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1379238A1 (enExample) |
| JP (1) | JP2005503339A (enExample) |
| CN (1) | CN1514727A (enExample) |
| AR (1) | AR033465A1 (enExample) |
| BR (1) | BR0205970A (enExample) |
| CA (1) | CA2442591A1 (enExample) |
| IL (1) | IL158071A0 (enExample) |
| MX (1) | MXPA03009277A (enExample) |
| PE (1) | PE20021032A1 (enExample) |
| WO (1) | WO2002085351A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| WO2004100991A1 (en) * | 2003-05-15 | 2004-11-25 | Universite Catholique De Louvain | Use of endothelin-1 antagonists for improving cancer therapy |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| CA2652345A1 (en) * | 2006-05-15 | 2007-11-22 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of sleep apnea related applications |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| CN117751099A (zh) * | 2021-08-05 | 2024-03-22 | 中国药科大学 | 酰胺类化合物及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR200000993T2 (tr) * | 1997-08-04 | 2000-12-21 | Abbott Laboratories | Endotelin antagonistleri. |
-
2002
- 2002-04-11 PE PE2002000305A patent/PE20021032A1/es not_active Application Discontinuation
- 2002-04-11 AR ARP020101335A patent/AR033465A1/es not_active Application Discontinuation
- 2002-04-11 CN CNA028116720A patent/CN1514727A/zh active Pending
- 2002-04-11 EP EP02726727A patent/EP1379238A1/en not_active Ceased
- 2002-04-11 JP JP2002582924A patent/JP2005503339A/ja active Pending
- 2002-04-11 CA CA002442591A patent/CA2442591A1/en not_active Abandoned
- 2002-04-11 BR BR0205970-3A patent/BR0205970A/pt not_active IP Right Cessation
- 2002-04-11 WO PCT/US2002/011397 patent/WO2002085351A1/en not_active Ceased
- 2002-04-11 MX MXPA03009277A patent/MXPA03009277A/es unknown
- 2002-04-11 IL IL15807102A patent/IL158071A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20021032A1 (es) | 2002-11-12 |
| JP2005503339A (ja) | 2005-02-03 |
| AR033465A1 (es) | 2003-12-17 |
| BR0205970A (pt) | 2003-09-30 |
| WO2002085351A1 (en) | 2002-10-31 |
| EP1379238A1 (en) | 2004-01-14 |
| MXPA03009277A (es) | 2004-03-10 |
| CA2442591A1 (en) | 2002-10-31 |
| CN1514727A (zh) | 2004-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002243495A1 (en) | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer | |
| AU2002352820A8 (en) | Calibration of tissue densities in computerized tomography | |
| AU2003275029A8 (en) | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues | |
| AU2004207813A8 (en) | Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles | |
| IL157364A0 (en) | Therapeutic methods and agents for diseases associated with decreased expression of aop-1 gene or aop-1 | |
| EP1587837A3 (en) | Prostate cancer diagnosis and treatment | |
| AU2002323258A1 (en) | Diagnosis and treatment of vascular disease | |
| AU2002327792A1 (en) | Diagnosis and treatment of diseases caused by mutations in cd72 | |
| IL158532A0 (en) | Treatment and diagnosis of macrophage mediated disease | |
| AU2002251366A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| PL368458A1 (en) | Improved use of antitumoral compound in cancer therapy | |
| EP1463495A4 (en) | AGENTS AND METHODS FOR TREATING CANCER | |
| AU2001240909A1 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| AU2002326813A1 (en) | Diagnosis and treatment of vascular disease | |
| MXPA03009277A (es) | Modulacion favorable de calidad de vida relacionada con la salud y progreso de la enfermedad con el paso del tiempo ajustado a la calidad relacionada con la salud en pacientes con cancer de prostata. | |
| HUP0302233A3 (en) | Methods of treating viral diseases with il-18 and il-18 combinations | |
| AU2002257139A1 (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| HK1061650A (en) | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer | |
| AU2001233955A1 (en) | Diagnosis and treatment of bipolar affective disorder | |
| AU2003263036A8 (en) | Span-xb gene and protein for the diagnosis and treatment of cancer | |
| AU2003250912A1 (en) | Agents and methods for diagnosis and therapy of cancer and cancer risk assessment | |
| AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
| AU2002251367A1 (en) | Proteins and genes for diagnosis and treatment of erbb2-related cancer | |
| AU4135600A (en) | Prostate cancer associated human fibronectin gene and biallelic markers | |
| IL169369A0 (en) | Thienopyridazinones and their use in modulation of autoimmune disease |